Stifel starts MEI Pharma at buy
Stifel Nicolaus has initiated coverage of MEI Pharma (NASDAQ:MEIP) with a “buy” rating and $11 target price. The stock closed at $7.95 on Monday. “We view MEI’s lead clinical candidate Pracinostat as...
View ArticleRoth adds MEI Pharma to Focus List, ups price target to $22
Roth Capital Partners has added “buy-rated” MEI Pharma (NASDAQ:MEIP) to its Focus List and raised its price target to $22 from $20. The stock closed at $7.68 on Wednesday. Analyst Joseph Pantginis...
View Article